

Claudio Fozza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1078438/publications.pdf>

Version: 2024-02-01

118
papers

2,405
citations

279701

23
h-index

233338

45
g-index

119
all docs

119
docs citations

119
times ranked

3851
citing authors

#	ARTICLE	IF	CITATIONS
1	Secondary thrombocytopenia after SARS-CoV-2 vaccine: Report of a case of hemorrhage and hematoma after minor oral surgery. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2022, 123, 95-97.	0.5	6
2	Physicians's Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform. <i>Frontiers in Oncology</i> , 2022, 12, 826040.	1.3	5
3	Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications. <i>Leukemia Research</i> , 2022, 117, 106856.	0.4	5
4	Efficacy and safety of azathioprine during remission of immune-mediated thrombotic thrombocytopenic purpura. <i>Blood Advances</i> , 2022, 6, 5463-5466.	2.5	2
5	Iron deficiency anaemia and low BMI among adolescent girls in India: the transition from 2005 to 2015. <i>Public Health Nutrition</i> , 2021, 24, 1577-1582.	1.1	8
6	Cytomegalovirus reactivation in patients under immunosuppressive treatment for autoimmune haemolytic anaemia. <i>Annals of Hematology</i> , 2021, , 1.	0.8	1
7	Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 271-279.	1.2	4
8	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021, 100, 2005-2014.	0.8	14
9	Clarifying the molecular mechanism of tomentosin-induced antiproliferative and proapoptotic effects in human multiple myeloma via gene expression profile and genetic interaction network analysis. <i>International Journal of Molecular Medicine</i> , 2021, 48, .	1.8	2
10	Tomentosin a Sesquiterpene Lactone Induces Antiproliferative and Proapoptotic Effects in Human Burkitt Lymphoma by Dereglulation of Anti- and Pro-Apoptotic Genes. <i>Life</i> , 2021, 11, 1128.	1.1	4
11	Assessment of Bone Metabolism Alterations in Transfusion-dependent Beta-thalassemia Major: An Observational Study. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, 118-119.	0.3	0
12	Efficacy and Safety of Azathioprine during Remission of Immune-Mediated Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2021, 138, 773-773.	0.6	7
13	The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 115-115.	0.6	2
14	Clinical Utility and Physician Perceptions of a Digital Platform for Electronic Patient-Reported Outcomes Monitoring in Patients with Hematologic Malignancies in Real-World Practice. <i>Blood</i> , 2021, 138, 4017-4017.	0.6	1
15	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020, 301, 163-166.	0.8	21
16	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	3.3	46
17	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. <i>Leukemia</i> , 2020, 34, 488-498.	3.3	35
18	Levels and Clinical Significance of Regulatory B Cells and T Cells in Acute Myeloid Leukemia. <i>BioMed Research International</i> , 2020, 2020, 1-6.	0.9	9

#	ARTICLE	IF	CITATIONS
19	White Blood Cell Count Nadir and Duration of Aplasia Do Not Associate with Treatment Outcome in Adult Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy. <i>Chemotherapy</i> , 2020, 65, 110-114.	0.8	4
20	NPM1-Mutated Myeloid Neoplasms with $\geq 20\%$ Blasts: A Really Distinct Clinico-Pathologic Entity?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8975.	1.8	26
21	Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. <i>Hematological Oncology</i> , 2020, 38, 607-610.	0.8	1
22	Occurrence of immune thrombocytopenic purpura in a patient with essential thrombocythemia: How the immune system can overcome a neoplastic clone. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2132-2134.	0.2	2
23	Syk Kinase Inhibitors Synergize with Artemisinins by Enhancing Oxidative Stress in Plasmodium falciparum-Parasitized Erythrocytes. <i>Antioxidants</i> , 2020, 9, 753.	2.2	23
24	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2020, 99, 1525-1530.	0.8	9
25	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020, 10, 66.	2.8	6
26	Rectal involvement in pre-early T acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2020, 99, 1151-1152.	0.8	0
27	MicroRNA-181a-3p as a diagnostic and prognostic biomarker for acute myeloid leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020012.	0.5	7
28	Antiproliferative and proapoptotic effects of <i>Inula viscosa</i> extract on Burkitt lymphoma cell line. <i>Tumor Biology</i> , 2020, 42, 101042831990106.	0.8	15
29	Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE) <i>Tj ETQq1 1 0.78484 rgBT4Overlo</i>		
30	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
31	The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 51-57.	2.0	7
32	Hematological, biochemical and antioxidant indices variations in regular blood donors among Mediterranean regions. <i>Transfusion and Apheresis Science</i> , 2019, 58, 102659.	0.5	4
33	Acute lymphoblastic leukemia in a nine-year-old girl with isodicentric chromosome 15 syndrome. <i>Cancer Genetics</i> , 2019, 235-236, 93-94.	0.2	2
34	A real-world study on Clofarabine and Cytarabine combination in patients with relapsed/refractory acute myeloid leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019032.	0.5	1
35	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019, 98, 1885-1890.	0.8	10
36	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. <i>International Journal of Cardiology</i> , 2019, 288, 124-127.	0.8	19

#	ARTICLE	IF	CITATIONS
37	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019, 37, 296-302.	0.8	53
38	Acute basophilic leukemia with U2AF1 mutation. <i>Blood Cells, Molecules, and Diseases</i> , 2019, 76, 63-65.	0.6	3
39	Flow Cytometry Assessment of CD26 + Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 294-299.	0.7	28
40	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290.	2.5	66
41	Pseudo-thrombocytopenia after autologous stem cell transplantation. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 66-67.	0.5	2
42	Deciphering the prognostic significance of autoimmune disorders in myelodysplastic syndromes. <i>Annals of Hematology</i> , 2019, 98, 1025-1026.	0.8	2
43	Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 112-119.	2.0	4
44	Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party. <i>Blood</i> , 2019, 134, 2931-2931.	0.6	2
45	Correlation of Oxidative Stress Biomarkers and Hematological Parameters in Blood Cancer Patients from Sardinia, Italy. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2019, 13, 49-57.	0.3	4
46	Primary extranodal vaginal non-hodgkin lymphoma: Diagnostic pitfalls and therapeutic challenges. <i>Histology and Histopathology</i> , 2019, 34, 723-730.	0.5	1
47	A case-report of a pulmonary tuberculosis with lymphadenopathy mimicking a lymphoma. <i>International Journal of Infectious Diseases</i> , 2018, 70, 38-41.	1.5	7
48	Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency. <i>European Journal of Haematology</i> , 2018, 101, 78-85.	1.1	5
49	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018, 93, E159-E161.	2.0	26
50	Evidence of a skewed T-cell repertoire in patients with light chain amyloidosis. <i>Hematological Oncology</i> , 2018, 36, 492-494.	0.8	3
51	The burden of autoimmunity in myelodysplastic syndromes. <i>Hematological Oncology</i> , 2018, 36, 15-23.	0.8	14
52	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2379-2380.	13.9	0
53	Increased Frequency of Immune Thrombocytopenic Purpura in Coeliac Disease and Vice Versa: A Prospective Observational Study. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-4.	0.7	5
54	Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. <i>Blood</i> , 2018, 132, 2293-2293.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors. <i>Blood</i> , 2018, 132, 3006-3006.	0.6	1
56	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. <i>Blood</i> , 2018, 132, 43-43.	0.6	10
57	Epstein-Barr virus infection is associated to patients with multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Leukemia and Lymphoma</i> , 2017, 58, 466-469.	0.6	8
58	Few-Layer Graphene Kills Selectively Tumor Cells from Myelomonocytic Leukemia Patients. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 3014-3019.	7.2	59
59	Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia. <i>Acta Haematologica</i> , 2017, 137, 15-16.	0.7	0
60	Few-Layer Graphene Kills Selectively Tumor Cells from Myelomonocytic Leukemia Patients. <i>Angewandte Chemie</i> , 2017, 129, 3060-3065.	1.6	9
61	Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2558-2564.	0.6	8
62	Safe fluoroquinolones prophylaxis in blood cancer patients with chemotherapy-induced neutropenia and Glucose-6-Phosphate-Dehydrogenase deficiency. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 733-737.	0.7	0
63	Pregnancy Outcome among Women with Beta-Thalassemia Major in North Sardinia. <i>Acta Haematologica</i> , 2017, 138, 166-167.	0.7	8
64	Study of the T-cell receptor repertoire by CDR3 spectratyping. <i>Journal of Immunological Methods</i> , 2017, 440, 1-11.	0.6	23
65	Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 605-612.	0.8	299
66	Total antioxidant capacity in Mediterranean β^2 -thalassemic patients. <i>Advances in Clinical and Experimental Medicine</i> , 2017, 26, 789-793.	0.6	14
67	Molecular and Genomic Impact of Large and Small Lateral Dimension Graphene Oxide Sheets on Human Immune Cells from Healthy Donors. <i>Advanced Healthcare Materials</i> , 2016, 5, 276-287.	3.9	90
68	Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients. <i>Journal of Hematology and Oncology</i> , 2016, 9, 63.	6.9	18
69	The immune landscape of myelodysplastic syndromes. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 90-99.	2.0	37
70	A genome-wide association study by ImmunoChip reveals potential modifiers in myelodysplastic syndromes. <i>Experimental Hematology</i> , 2016, 44, 1034-1038.	0.2	4
71	Isolated polyglobulia as an uncommon presentation of chronic myeloid leukaemia. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 56, 37.	0.6	2
72	Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis. <i>American Journal of Hematology</i> , 2015, 90, E141.	2.0	16

#	ARTICLE	IF	CITATIONS
73	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. <i>American Journal of Hematology</i> , 2015, 90, E80-5.	2.0	93
74	Derangement of the T-cell repertoire in patients with B-cell non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2015, 94, 298-309.	1.1	13
75	Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. <i>Leukemia Research</i> , 2015, 39, 957-963.	0.4	32
76	The role of Clofarabine in the treatment of adults with acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 237-245.	2.0	10
77	Pseudothrombocytopenia in a patient receiving romiplostim for immune thrombocytopenic purpura. <i>Annals of Hematology</i> , 2014, 93, 899-900.	0.8	4
78	Strabismus and diplopia in a patient with acute myeloid leukemia. <i>American Journal of Case Reports</i> , 2014, 15, 288-290.	0.3	8
79	Anaplastic Large Cell Lymphoma of the Breast Arising Around Mammary Implant Capsule: An Italian Report. <i>Aesthetic Plastic Surgery</i> , 2013, 37, 567-571.	0.5	25
80	T-cell receptor repertoire usage in hematologic malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 201-211.	2.0	11
81	The role of T-cells in the pathogenesis of myelodysplastic syndromes: Passengers and drivers. <i>Leukemia Research</i> , 2013, 37, 201-203.	0.4	25
82	A novel pattern of uridine diphosphate glucuronosyltransferase polymorphisms associated with hyperbilirubinemia during nilotinib treatment. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 51, 162.	0.6	3
83	Rituximab Maintenance or Retreatment After Autologous Transplantation for Relapsed Follicular Lymphoma?. <i>Journal of Clinical Oncology</i> , 2013, 31, 3846-3847.	0.8	0
84	Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. <i>Blood</i> , 2013, 122, 2659-2659.	0.6	0
85	Patients with Early-Stage Myelodysplastic Syndromes Show Increased Frequency of CD4+CD25high+CD127low Regulatory T Cells. <i>Acta Haematologica</i> , 2012, 128, 178-182.	0.7	21
86	Unbalanced 1q Whole-Arm Translocation Resulting in der(14)t(1;14)(q11;q12;p11) in Myelodysplastic Syndrome. <i>Cytogenetic and Genome Research</i> , 2012, 136, 256-263.	0.6	3
87	Large B-cell non-Hodgkin lymphoma relapsing with meningeal localization. <i>Blood</i> , 2012, 119, 6185-6185.	0.6	1
88	T-cell receptor repertoire analysis in monozygotic twins concordant and discordant for type 1 diabetes. <i>Immunobiology</i> , 2012, 217, 920-925.	0.8	17
89	CD4+ and CD8+ T-Cell Skewness in Classic Kaposi Sarcoma. <i>Neoplasia</i> , 2012, 14, 487-494.	2.3	15
90	Regulatory T cells in stem cell transplantation: Main characters or walk-on actors?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 18-25.	2.0	8

#	ARTICLE	IF	CITATIONS
91	Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-107). <i>British Journal of Haematology</i> , 2012, 156, 205-212.	1.2	65
92	Patients with myelodysplastic syndromes show reduced frequencies of CD4 ⁺ CD8 ⁺ double-positive T cells. <i>European Journal of Haematology</i> , 2012, 88, 89-90.	1.1	11
93	Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?. <i>European Journal of Haematology</i> , 2012, 88, 380-387.	1.1	19
94	TCRBV20S1 polymorphism does not influence the susceptibility to type 1 diabetes and multiple sclerosis in the Sardinian population. <i>Immunogenetics</i> , 2012, 64, 153-154.	1.2	5
95	Keratitis-Ichthyosis-Deafness Syndrome, Atypical Connexin GJB2 Gene Mutation, and Peripheral T-Cell Lymphoma: More Than a Random Association?. <i>Case Reports in Hematology</i> , 2011, 2011, 1-3.	0.3	1
96	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 6521-6528.	0.6	395
97	Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas. <i>Advances in Hematology</i> , 2011, 2011, 1-4.	0.6	4
98	T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications. <i>Advances in Hematology</i> , 2011, 2011, 1-8.	0.6	16
99	Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223. <i>Haematologica</i> , 2010, 95, 1114-1121.	1.7	45
100	Efficacy of rituximab in autoimmune hemolytic anemia associated with splenic marginal zone lymphoma. <i>Annals of Hematology</i> , 2010, 89, 113-114.	0.8	2
101	Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107). <i>Blood</i> , 2010, 116, 510-510.	0.6	2
102	Prompt recovery of chemotherapy associated Hand-Foot syndrome treated with acetylsalicylic acid in two patients with Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2009, 82, 164-164.	1.1	1
103	Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4 ⁺ subset and oligoclonal in the CD8 ⁺ subset. <i>Experimental Hematology</i> , 2009, 37, 947-955.	0.2	70
104	A case of coexistence between JAK2V617F and BCR /ABL. <i>European Journal of Haematology</i> , 2008, 81, 75-76.	1.1	18
105	Breakthrough cutaneous alternariosis in a patient with acute lymphoblastic leukemia: Clinical features and diagnostic issues. <i>Leukemia and Lymphoma</i> , 2008, 49, 154-155.	0.6	5
106	T-cell receptor repertoire usage after allografting differs between CD4 ⁺ CD25 ⁺ regulatory T cells and their CD4 ⁺ CD25 ⁻ counterpart. <i>Haematologica</i> , 2007, 92, 206-214.	1.7	15
107	High Frequency of the TCRBV20S1 Null Allele in the Sardinian Population. <i>Human Immunology</i> , 2007, 68, 426-429.	1.2	4
108	Disease relapse after haematopoietic stem cell transplantation: Risk factors and treatment. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 311-327.	0.7	36

#	ARTICLE	IF	CITATIONS
109	Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. <i>Leukemia</i> , 2007, 21, 943-948.	3.3	46
110	Reply to "Splenuctomy status of the patient may have impact on response to donor lymphocyte infusions" by Duygu Uckan-Åetinkaya et al.. <i>Leukemia</i> , 2007, 21, 2050-2051.	3.3	0
111	Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. <i>British Journal of Haematology</i> , 2007, 136, 833-836.	1.2	25
112	Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. <i>Blood</i> , 2006, 107, 473-479.	0.6	109
113	Acquired hemophilia in a patient affected by acute myeloid leukemia. <i>American Journal of Hematology</i> , 2005, 79, 81-82.	2.0	7
114	Two cases of chronic lymphoproliferative disorders in psoriatic patients treated with cyclosporine: hairy cell leukemia and Waldenstrom macroglobulinemia. <i>European Journal of Dermatology</i> , 2005, 15, 271-3.	0.3	9
115	Cytogenetic and hematological spontaneous remission in a case of acute myelogenous leukemia. <i>European Journal of Haematology</i> , 2004, 73, 219-222.	1.1	30
116	Long-lasting fever of unknown origin preceding the diagnosis of intravascular lymphomatosis: A further case stimulates some remarks. <i>American Journal of Hematology</i> , 2003, 74, 211-213.	2.0	17
117	T-cell receptor repertoire in healthy Sardinian subjects. <i>Human Immunology</i> , 2003, 64, 689-695.	1.2	7
118	Correlation of Oxidative Stress Biomarkers and Hematological Parameters in Blood Cancer Patients from Sardinia, Italy. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 0, , .	0.3	8